Two Sigma Advisers
SNDX icon

Two Sigma Advisers’s Syndax Pharmaceuticals SNDX Stock Holding History

Two Sigma Advisers’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-632,752
Closed -$13.3M – 1839
2025
Q4 		$13.3M Buy
632,752
+249,700
+65% +$4.36M 0.03% 453
2025
Q3 		$5.89M Sell
383,052
-9,400
-2% -$123K 0.01% 681
2025
Q2 		$3.68M Sell
392,452
-110,700
-22% -$1.22M 0.01% 855
2025
Q1 		$6.18M Sell
503,152
-32,800
-6% -$463K 0.01% 696
2024
Q4 		$7.09M Sell
535,952
-133,400
-20% -$2.28M 0.02% 586
2024
Q3 		$12.9M Buy
669,352
+48,100
+8% +$994K 0.03% 420
2024
Q2 		$12.8M Buy
621,252
+165,400
+36% +$3.46M 0.03% 463
2024
Q1 		$10.8M Buy
455,852
+304,400
+201% +$6.79M 0.03% 513
2023
Q4 		$3.27M Buy
151,452
+84,400
+126% +$1.3M 0.01% 1026
2023
Q3 		$974K Sell
67,052
-70,100
-51% -$1.33M ﹤0.01% 1535
2023
Q2 		$2.87M Sell
137,152
-126,200
-48% -$2.63M 0.01% 1018
2023
Q1 		$5.56M Sell
263,352
-54,500
-17% -$1.36M 0.01% 764
2022
Q4 		$8.09M Sell
317,852
-53,900
-14% -$1.26M 0.02% 578
2022
Q3 		$8.93M Buy
371,752
+18,900
+5% +$424K 0.03% 526
2022
Q2 		$6.79M Sell
352,852
-15,500
-4% -$258K 0.02% 641
2022
Q1 		$6.4M Buy
368,352
+13,800
+4% +$232K 0.02% 696
2021
Q4 		$7.76M Buy
354,552
+12,700
+4% +$235K 0.02% 589
2021
Q3 		$6.53M Sell
341,852
-86,600
-20% -$1.44M 0.02% 669
2021
Q2 		$7.36M Sell
428,452
-153,300
-26% -$2.81M 0.02% 683
2021
Q1 		$13M Sell
581,752
-85,800
-13% -$1.94M 0.04% 478
2020
Q4 		$14.8M Buy
667,552
+408,500
+158% +$8.47M 0.04% 427
2020
Q3 		$3.82M Buy
259,052
+58,500
+29% +$892K 0.01% 864
2020
Q2 		$2.97M Buy
200,552
+149,000
+289% +$2.27M 0.01% 1011
2020
Q1 		$566K Buy
51,552
+17,100
+50% +$160K ﹤0.01% 1748
2019
Q4 		$302K Buy
+34,452
New +$253K ﹤0.01% 2061

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Two Sigma Advisers's SNDX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 632,752 shares — an estimated $13.3M sold.

Two Sigma Advisers first reported a position in SNDX in Q4 2019 and held it in 25 quarters. The position peaked at $14.8M in Q4 2020. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 632,752 Syndax Pharmaceuticals shares in Q1 2026, an estimated $13.3M.
  • Two Sigma Advisers first reported a position in Syndax Pharmaceuticals in Q4 2019 and held it in 25 quarters.
  • Two Sigma Advisers's Syndax Pharmaceuticals position peaked at $14.8M in Q4 2020.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.